Dustri Online Services

Books: 0	Journals: 1	Articles: 5

Abstract

Allergologie select, Vol. 5/2021 (293-304)

Janus kinase inhibitors for the therapy of atopic dermatitis

Stephan Traidl, Sina Freimooser, and Thomas Werfel

Department of Dermatology, Allergology and Venereology, Hannover Medical School, Hannover, Germany
The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual receptor-associated kinases, thereby preventing the mediation of inflammatory signals. Several JAK inhibitors with varying mechanism of action, potency, and safety represent potential therapeutic options for AD in both topical and systemic application. The JAK1/2 selective JAK inhibitor baricitinib was the first substance from this class of drugs approved by the EMA for the systemic oral treatment of AD. The clinical development program of the JAK1 selective inhibitors upadacitinib and abrocitinib is finalized with positive results for AD. The PAN-JAK inhibitor delgocitinib was the first substance being approved for the treatment of AD (in Japan). This review article covers the rising data on investigational and approved JAK inhibitors in the context of the treatment of AD.Correspondence to:
Stephan Traidl, MD, Clinic for Dermatology, Allergology and Venereology, Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hanover, Germany
Email: [email protected]

Abstract

Allergologie select, Vol. 7/2023 (1-7)

Prospective, monocentric, observational study of the long-term effectiveness of omalizumab in chronic urticaria

Stephan Traidl and Bettina Wedi

Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
Omalizumab, a monoclonal antibody targeting IgE, has been approved in 2014 for the treatment of H1 antihistaminerefractory chronic urticaria. Data on longterm effectiveness and predictive factors for treatment response are currently limited. In this monocentric, prospective, observational study, 112 patients with chronic spontaneous urticaria (CSU) and 32 patients with chronic inducible urticaria (CIndU) were included. In addition to a rapid response, omalizumab also showed good effectiveness on both forms of chronic urticaria over 2 years. Low total IgE and elevated Yersinia IgA were identified as potential predictive markers for slower treatment responses in CSU. In conclusion, the present study highlights the efficacy of omalizumab for the treatment of chronic urticaria. With emerging new therapeutic options for chronic urticaria, further genetic as well as molecular markers are needed to establish patientspecific therapy selection.Correspondence to:
Dr. med. Stephan Traidl, Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
Email: [email protected]

Abstract

Allergologie select, Vol. 8/2024 (365-406)

Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions

Uta Jappe¹#², Karl-Christian Bergmann³, Folke Brinkmann⁴, Valentina Faihs⁵, Askin Gülsen⁶, Ludger Klimek⁷, Harald Renz⁸, Sebastian Seurig⁹, Christian Taube¹⁰, Stephan Traidl¹¹, Regina Treudler¹², Martin Wagenmann¹³, Thomas Werfel¹¹, Margitta Worm¹⁴, and Torsten Zuberbier³

¹Division Clinical and Molecular Allergology, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, ²Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University Medical Center Schleswig-Holstein, Campus Lübeck, University of Lübeck, ³Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, ⁴Division of Pediatric Pulmonology and Allergology, University Children’s Hospital, German Center for Lung Research (ARCN, DZL), Lübeck, ⁵Department of Dermatology and Allergy Biederstein, Klinikum rechts der Isar, Technical University of Munich, ⁶Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Duesseldorf, ⁷Center for Rhinology and Allergology, Wiesbaden, ⁸Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps Universität Marburg, Member of the German Center for Lung Research (DZL) Marburg, ⁹Interdisciplinary Allergy Center Nuremberg (NIZA), Department of Internal Medicine ³, Pneumology, Nuremberg Hospital, Nuremberg, ¹⁰Department of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Essen, ¹¹Department of Dermatology and Allergy, Hannover Medical School, Hannover, ¹²Institute of Allergology IFA, Charité Universitätsmedizin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, ¹³Department of Otorhinolaryngology, Düsseldorf University Hospital, Heinrich Heine University, Düsseldorf, ¹⁴Division of Allergy and Immunology, Department of Dermatology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany
The development of targeted therapies for atopic diseases, urticaria, and angioedema with biologics is progressing rapidly: New “targets” of clinical-therapeutic relevance have been identified, the corresponding targeted antibodies developed, tested in clinical trials, and approved for therapy. These include the anti-IgE antibody omalizumab (also effective and approved for the treatment of urticaria), the anti-IL-4/13 receptor-specific antibody dupilumab, the two anti-IL-13 antibodies lebrikizumab and tralokinumab, the anti-TSLP antibody tezepelumab, the two anti-IL-5 antibodies mepolizumab and reslizumab, and the anti-IL5 receptor-specific antibody benralizumab for the treatment of atopic diseases. For the treatment of hereditary angioedema, C1 inhibitor and the antibody lanadelumab (directed against kallikrein) have also long been approved as biologics in addition to low-molecular substances. Other therapeutic antibodies are in various stages of development. Furthermore, the range of indications for some very effective biologics has been successfully expanded to include additional diseases. In this context, the first results on biologic therapy of food allergy and eosinophilic esophagitis are interesting. Biologics that address different target structures are also increasingly being administered in combination, either simultaneously or sequentially, in order to achieve optimal efficacy. A developing area is the use of biologics in children and the observation of immunological and non-immunological side effects. In some cases, new unexpected side effects and hypersensitivity reactions have emerged, which in turn raise pathomechanistic questions, such as conjunctivitis with dupilumab therapy, which only appears to occur in the treatment of atopic dermatitis but not in the treatment of other atopic diseases. In dermatology, paradoxical reactions have been described under therapy with some biologics. And immune reactions of type alpha to epsilon to biologics (hypersensitivity reactions) continue to be a clinically relevant problem, whereby the selection of an alternative therapeutic agent is a challenge and the diagnostics that support this have not yet been sufficiently incorporated into routine work.Correspondence to:
Prof. Dr. med. Uta Jappe, Division Clinical and Molecular Allergology, Research Center Borstel, Leibniz Lung Center, Parkallee 35, 23845 Borstel, Germany
Email: [email protected]

Abstract

Allergologie select, Vol. 9/2025 (75-79)

AI – one size fits all?

Stephan Traidl¹, Sonja Mathes², and Sebastian Seurig³

¹Department of Dermatology and Allergy, Hannover Medical School, Hanover, ²Department of Dermatology and Allergy, School of Medicine and Health, Technical University of Munich, Munich, and ³Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuremberg, Campus North, Paracelsus Medical University, Nuremberg, Germany
The use of artificial intelligence (AI) in medicine requires a careful selection of suitable models, as there is no universal “one size fits all” method. While linear regression is convincing due to its simplicity and interpretability, it is limited due to the assumption of linearity and susceptibility to multicollinearity and outliers. More complex approaches such as neural networks show their strengths in the detection of non-linear patterns and automatic feature extraction but require large amounts of data, high computing capacity, and suffer from limited explainability. Principal component analysis (PCA) offers an efficient reduction of dimensionality. Ultimately, the choice of model depends on the balance between accuracy, interpretability, and data availability. A selection of machine learning models is presented in this article.Correspondence to:
PD Dr. med. Stephan Traidl, MSc, Department of Dermatology and Allergy, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hanover, Germany
Email: [email protected]

Abstract

Allergologie select, Vol. 9/2025 (86-92)

Ethical aspects of the application of artificial intelligence in allergology

Sonja Mathes¹, Sebastian Seurig², Stephan Traidl³, Valentina Faihs¹, Marta Dechant¹, Knut Brockow¹, and Ulf Darsow¹

¹Department of Dermatology and Allergy, School of Medicine and Health, Technische Universität München, Munich, ²Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuremberg, Campus North, Paracelsus Medical University, Nuremberg, and ³Department of Dermatology and Allergy, Hannover Medical School, Hanover, Germany
Background: Artificial intelligence (AI) offers a wide range of applications in allergology, including diagnostics and disease course prediction, consultations, real-time monitoring of allergic reactions, and support for decentralized clinical studies. Materials and methods: This review aims to highlight not only the potential applications but also the ethical aspects of using AI in allergology. Results: Initial studies demonstrate potential applications of AI in predicting provocation tests and antibiotic delabeling. However, these models from research and development have not yet been established in clinical practice, partly because ethical considerations, alongside technical challenges, and data quality issues, must be addressed. Key ethical dilemmas include bias and fairness, the principle of nonmaleficence, data protection and autonomy, transparency of AI models, and questions of accountability. AI applications must be robust and reliable to prevent harm caused by erroneous recommendations. Conclusion: The use of AI in allergology requires clear guidelines based on principles such as autonomy, justice, and non-maleficence. General bioethical principles must be complemented by specific regulations for AI.Correspondence to:
Dr. med. Sonja Mathes, Klinik und Poliklinik für Dermatologie und Allergologie, Biedersteiner Straße 29, 80802 Munich, Germany
Email: [email protected]

Warenkorb Übersicht
Typ	Anz	Rabatt	MwSt	Preis
Der Warenkorb ist leer

Ihr Warenkorb

Search Results

Warenkorb Übersicht

Senden Sie uns eine E-Mail